Strategies and opportunities for drug development in heart failure

JAMA

Volumn 309, Issue 15, 2013, Pages 1593-1594

  Butler, Javed ^a   Fonarow, Gregg C ^b   Gheorghiade, Mihai ^c  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGING; CARDIOVASCULAR RISK; COMORBIDITY; DISEASE COURSE; DRUG DEVELOPMENT; DYSPNEA; HEART FAILURE; HEART HEMODYNAMICS; HOSPITALIZATION; HUMAN; PATIENT IDENTIFICATION; PATIENT SAFETY; PRIORITY JOURNAL; SHORT SURVEY; STRATEGIC PLANNING; ARTICLE; CLINICAL TRIAL (TOPIC); MORTALITY; PATHOPHYSIOLOGY; POPULATION DYNAMICS; REGISTER; RISK; TREATMENT OUTCOME;

BIOLOGICAL MARKER;

BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DYSPNEA; HEART FAILURE; HOSPITALIZATION; HUMANS; POPULATION DYNAMICS; REGISTRIES; RISK; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84876337749     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.1063     Document Type: Short Survey

References (3)

1. Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol. 2013;61(4):391-403.
2. Gheorghiade M, Pang PS. Are BNP changes during hospitalization for heart failure a reliable surrogate for predicting the effects of therapies on postdischarge mortality? J Am Coll Cardiol. 2009;53(25):2349-2352.
3. Gheorghiade M, Vaduganathan M, Greene SJ, et al. Site selection in global clinical trials in patients hospitalized for heart failure [published online first October 26, 2012]. Heart Fail Rev. doi:10.1007/s10741-012-9361-8.